pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 44
- Patents
- 0
Docetaxel
Phase 3 · small molecule · Non-small Cell Lung Cancer
Docetaxel for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code D4200C00032
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Non-small Cell Lung Cancer
- Status
- completed
- Trials
- 1